In the infant vaccine group , 5/9 infants exhibited either IgA or SNA seroconversion and 7/9 infants had evidence of RV3-BB replication on days 3-6 , compared with 2/7 infants who seroconverted and 0/10 infants with evidence of replication in the placebo group .
